Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0851

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients ; volume:69 ; number:5 ; day:12 ; month:2 ; year:2020 ; pages:771-777 ; date:5.2020
Cancer immunology immunotherapy ; 69, Heft 5 (12.2.2020), 771-777, 5.2020

Creator: Hurkmans, Daan P.
Kuipers, Merian E.
Smit, Jasper
Marion, Ronald van
Mathijssen, Ron H. J.
Postmus, Piet E.
Hiemstra, Pieter S.
Aerts, Joachim G. J. V.
Thüsen, Jan H. von der
Burg, Sjoerd H. van der

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-020-02506-x

URN: urn:nbn:de:101:1-2020070513511392783167

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hurkmans, Daan P.
Kuipers, Merian E.
Smit, Jasper
Marion, Ronald van
Mathijssen, Ron H. J.
Postmus, Piet E.
Hiemstra, Pieter S.
Aerts, Joachim G. J. V.
Thüsen, Jan H. von der
Burg, Sjoerd H. van der
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Hochschulschrift

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Hochschulschrift

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Hochschulschrift

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+CD38+, CD8+HLA-DR+ : Stellenwert dieser Lymphozytensubpopulationen als Surrogatmarker bei der HIV-Infektion

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

PD-L1 Expression und CD8 positive zytotoxische Lymphozyten in mesenchymalen Tumoren

HLA-DRB5 promotes immune thrombocytopenia via activating CD8 + T cells

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity

Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

Related objects

Reset password